Analysts Set LeMaitre Vascular, Inc. (NASDAQ:LMAT) Target Price at $100.20

LeMaitre Vascular, Inc. (NASDAQ:LMAT) has earned a consensus rating of “Moderate Buy” from the eight ratings firms that are covering the stock, Marketbeat reports. Four equities research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1-year target price among brokerages that have covered the stock in the last year is $100.20.

LMAT has been the topic of several research analyst reports. Roth Capital restated a “buy” rating and set a $108.00 target price on shares of LeMaitre Vascular in a research note on Wednesday, November 5th. Barrington Research reaffirmed an “outperform” rating and set a $95.00 price target on shares of LeMaitre Vascular in a research report on Wednesday, October 15th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $95.00 price objective on shares of LeMaitre Vascular in a research note on Monday, November 10th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of LeMaitre Vascular in a report on Monday, December 29th. Finally, Wells Fargo & Company dropped their price target on shares of LeMaitre Vascular from $97.00 to $93.00 and set an “equal weight” rating on the stock in a research note on Friday, November 7th.

LeMaitre Vascular Price Performance

LMAT opened at $86.50 on Tuesday. The firm has a market cap of $1.96 billion, a PE ratio of 37.28, a P/E/G ratio of 1.90 and a beta of 0.68. The stock has a 50-day moving average price of $84.62 and a 200-day moving average price of $87.33. LeMaitre Vascular has a 1 year low of $71.42 and a 1 year high of $105.55. The company has a debt-to-equity ratio of 0.44, a current ratio of 13.58 and a quick ratio of 11.45.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $0.62 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.57 by $0.05. LeMaitre Vascular had a return on equity of 14.06% and a net margin of 22.14%.The business had revenue of $61.05 million for the quarter, compared to analysts’ expectations of $62.18 million. During the same period in the prior year, the firm posted $0.49 EPS. The firm’s quarterly revenue was up 11.4% on a year-over-year basis. LeMaitre Vascular has set its FY 2025 guidance at 2.480-2.530 EPS and its Q4 2025 guidance at 0.640-0.690 EPS. Sell-side analysts predict that LeMaitre Vascular will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, December 4th. Shareholders of record on Thursday, November 20th were given a $0.20 dividend. The ex-dividend date was Thursday, November 20th. This represents a $0.80 dividend on an annualized basis and a yield of 0.9%. LeMaitre Vascular’s dividend payout ratio is presently 34.48%.

Institutional Investors Weigh In On LeMaitre Vascular

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Allspring Global Investments Holdings LLC lifted its position in LeMaitre Vascular by 9.6% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 3,145 shares of the medical instruments supplier’s stock worth $255,000 after buying an additional 275 shares during the last quarter. Chatham Capital Group Inc. lifted its stake in LeMaitre Vascular by 1.3% in the fourth quarter. Chatham Capital Group Inc. now owns 48,045 shares of the medical instruments supplier’s stock worth $3,896,000 after purchasing an additional 600 shares during the last quarter. Congress Asset Management Co. boosted its position in shares of LeMaitre Vascular by 5.8% during the fourth quarter. Congress Asset Management Co. now owns 732,331 shares of the medical instruments supplier’s stock valued at $59,392,000 after buying an additional 40,065 shares during the period. SG Americas Securities LLC grew its stake in shares of LeMaitre Vascular by 343.7% during the fourth quarter. SG Americas Securities LLC now owns 55,809 shares of the medical instruments supplier’s stock valued at $4,526,000 after buying an additional 43,230 shares during the last quarter. Finally, GAMMA Investing LLC grew its holdings in shares of LeMaitre Vascular by 32.7% in the fourth quarter. GAMMA Investing LLC now owns 727 shares of the medical instruments supplier’s stock worth $59,000 after purchasing an additional 179 shares during the last quarter. Institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.